EFFECTIVENESS OF RESEARCHAYU SPINOVEDA TREATMENT STRATEGY IN SPINE OSTEOPOROSIS AND SPONDYLOSIS: A RETROSPECTIVE MULTICENTRIC COHORT STUDY
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 180
- 试验地点
- 13
- 主要终点
- In our study, time points refer to the scheduled intervals at which outcome assessments will be carried out. All clinical outcomes (including VAS pain score, spinal range of motion, and morning stiffness) will be evaluated at baseline (before initiation of treatment), at 4 weeks, and at 8 weeks. These defined time points will allow comparison of patient outcomes over the treatment duration to assess the effectiveness of the Spinoveda treatment strategy.
研究概览
简要总结
The study titled Effectiveness of ResearchAyu Spineveda Treatment Strategy in Spine Osteoporosis and Spondylosis A Retrospective Multicentric Cohort Study aims to evaluate the clinical outcomes of patients who have received the Spineveda Treatment Strategy STS at multiple ResearchAyu centers. This retrospective observational analysis uses existing patient medical records to assess improvement in pain, mobility, and bone health parameters among patients diagnosed with spondylosis and osteoporosis.
Eligible patients of either gender aged between 30 and 85 years with documented diagnosis and follow up data are included. Data variables include demographic details, baseline disease profile, treatment details, Visual Analogue Scale VAS scores, Oswestry Disability Index ODI, bone mineral density reports, and biochemical parameters such as calcium and vitamin D.
The analysis measures changes in pain scores, improvement in functional ability, and quality of life after completion of the Spineveda treatment. The study is expected to provide real world evidence on the effectiveness and safety of the Ayurvedic Spineveda protocol in managing degenerative spine disorders and osteoporosis, supporting integrative and evidence based management approaches for chronic musculoskeletal conditions.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 30.00 Year(s) 至 85.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients of either sex aged between 30 to 85 years.
- •Diagnosed cases of degenerative spine diseases such as spondylosis (cervical, lumbar, or combined) and/or osteoporosis, confirmed by clinical and radiological findings.
- •Patients who have undergone the ResearchAyu Spineveda Treatment Strategy (STS) between January 2024 and February 2025 at participating centers.
- •Availability of complete baseline and follow-up data in the patient medical records.
- •Patients who had provided written informed consent for treatment and use of anonymized clinical data for research.
排除标准
- •Patients below 30 years or above 85 years of age.
- •Patients with infective, inflammatory, or traumatic spine disorders (such as Pott’s spine, ankylosing spondylitis, or fractures).
- •Patients with systemic rheumatoid arthritis, rheumatic heart disease, or autoimmune disorders likely to confound degenerative findings.
- •History of spine surgery, malignancy, or chronic corticosteroid use.
- •Pregnant or lactating women.
- •Patients with incomplete or missing baseline or follow-up data.
结局指标
主要结局
In our study, time points refer to the scheduled intervals at which outcome assessments will be carried out. All clinical outcomes (including VAS pain score, spinal range of motion, and morning stiffness) will be evaluated at baseline (before initiation of treatment), at 4 weeks, and at 8 weeks. These defined time points will allow comparison of patient outcomes over the treatment duration to assess the effectiveness of the Spinoveda treatment strategy.
时间窗: In our study, time points refer to the scheduled intervals at which outcome assessments will be carried out. All clinical outcomes (including VAS pain score, spinal range of motion, and morning stiffness) will be evaluated at baseline (before initiation of treatment), at 4 weeks, and at 8 weeks. These defined time points will allow comparison of patient outcomes over the treatment duration to assess the effectiveness of the Spinoveda treatment strategy.
次要结局
- Change in lumbar spine and femoral bone mineral density (BMD) as recorded in DEXA reports(Baseline and after 6 months of therapy)
研究者
Dr Poorva Sawant
ResearchAyu